Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

37.09
+0.74002.04%
Post-market: 37.00-0.0900-0.24%19:50 EDT
Volume:2.86M
Turnover:105.10M
Market Cap:43.21B
PE:61.82
High:37.11
Open:36.46
Low:36.06
Close:36.35
52wk High:38.37
52wk Low:18.21
Shares:1.17B
Float Shares:1.09B
Volume Ratio:0.60
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.57
PE(LYR):30.65

Loading ...

Mar 01, 2023

[Supp]Public Prospectus

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
Feb 13, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 08, 2023

Major Issues Report

8-K - Current report
Dec 20, 2022

Correspondence

CORRESP [Cover] - Correspondence
Nov 21, 2022

Major Issues Report

8-K - Current report
Nov 03, 2022

Major Issues Report

8-K - Current report
Nov 03, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 26, 2022

Correspondence

CORRESP [Cover] - Correspondence
Jul 27, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 26, 2022

Major Issues Report

8-K - Current report
Jun 23, 2022

Major Issues Report

8-K - Current report
May 03, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 03, 2022

Major Issues Report

8-K - Current report
Feb 24, 2022

Major Issues Report

8-K - Current report
Feb 11, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 09, 2022

Major Issues Report

8-K - Current report
Feb 09, 2022

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Dec 06, 2021

Statement Of Changes In Beneficial Ownership

3 - Initial statement of beneficial ownership of securities
Nov 08, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities